BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, November 8, 2024
See today's BioWorld
Home
» EMA grants 77 approvals in 2023, outpaces FDA in biosimilars
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
EMA grants 77 approvals in 2023, outpaces FDA in biosimilars
Jan. 16, 2024
By
Nuala Moran
No Comments
The EMA has once again come in behind the U.S. FDA, granting market access to 77 new products in 2023, fewer than half the 157 approvals the FDA processed in the 11 months from January through December 2023.
BioWorld
Regulatory
Biosimilar
Europe
EMA